Lapatinib plus capecitabine in patients with HER2-positive metastatic breast cancer

A systematic review

Rebecca Madden, Sam KOSARI, Gregory Peterson, Nasser Bagheri, Jackson THOMAS

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

Objective: Human epidermal growth factor receptor 2 (HER2)-positive breast cancer, which accounts for 20 – 25% of cases of breast cancers, is highly aggressive. Due to cardiotoxicity and increasing resistance associated with trastuzumab, the first-line treatment, there is a need for effective second-line therapies in treating HER2-positive breast cancer. In this context, there has been increasing interest in the combination of lapatinib plus capecitabine. The aim of this systematic review was to assess the efficacy of lapatinib plus capecitabine for HER2-positive breast cancer after progression with trastuzumab therapy, in comparison with capecitabine monotherapy and other agents such as vinorelbine and trastuzumab emtansine. Materials and methods: We performed a keyword search in five electronic databases (OVID MEDLINE, the Cochrane Library, Web of Science, SCOPUS, and CINAHL; January 2010 to April 2017) for trials in patients with HER2-positive breast cancer that has progressed on trastuzumab. After screening, the relevant studies were assessed for their methodological quality (including selection bias, randomization, control for confounders, and blinding) by two reviewers independently. Results and discussion: A total of 50 studies were identified; only 6 of those met the inclusion criteria and were analyzed. Five received a weak rating on the quality assessment tool, and none could be considered as being of high scientific quality after taking the risk of bias and other confounding variables into account. The studies demonstrated that lapatinib plus capecitabine is effective in extending median overall (OS) and progression-free survival (PFS) outcomes, achieving OS of 37.6 – 108.7 weeks and PFS of 21.1 – 30 weeks across studies. However, median OS and PFS for trastuzumab emtansine therapy were found to be considerably better (133.9 weeks and 41.6 weeks, respectively) than for lapatinib plus capecitabine. Conclusion: The results suggest that the combination of lapatinib plus capecitabine can improve PFS and OS in patients with HER2-positive breast cancer that has progressed on trastuzumab. However, it appears that trastuzumab emtansine provides better treatment outcomes in this context.

Original languageEnglish
Pages (from-to)72-80
Number of pages9
JournalInternational Journal of Clinical Pharmacology and Therapeutics
Volume56
Issue number2
DOIs
Publication statusPublished - 1 Jan 2018

Fingerprint

Breast Neoplasms
Disease-Free Survival
Library Science
Confounding Factors (Epidemiology)
Selection Bias
Therapeutics
Random Allocation
Risk-Taking
MEDLINE
Capecitabine
human ERBB2 protein
lapatinib
Databases
Trastuzumab
ado-trastuzumab emtansine

Cite this

@article{89876c4cc36341b5928fc43691df630a,
title = "Lapatinib plus capecitabine in patients with HER2-positive metastatic breast cancer: A systematic review",
abstract = "Objective: Human epidermal growth factor receptor 2 (HER2)-positive breast cancer, which accounts for 20 – 25{\%} of cases of breast cancers, is highly aggressive. Due to cardiotoxicity and increasing resistance associated with trastuzumab, the first-line treatment, there is a need for effective second-line therapies in treating HER2-positive breast cancer. In this context, there has been increasing interest in the combination of lapatinib plus capecitabine. The aim of this systematic review was to assess the efficacy of lapatinib plus capecitabine for HER2-positive breast cancer after progression with trastuzumab therapy, in comparison with capecitabine monotherapy and other agents such as vinorelbine and trastuzumab emtansine. Materials and methods: We performed a keyword search in five electronic databases (OVID MEDLINE, the Cochrane Library, Web of Science, SCOPUS, and CINAHL; January 2010 to April 2017) for trials in patients with HER2-positive breast cancer that has progressed on trastuzumab. After screening, the relevant studies were assessed for their methodological quality (including selection bias, randomization, control for confounders, and blinding) by two reviewers independently. Results and discussion: A total of 50 studies were identified; only 6 of those met the inclusion criteria and were analyzed. Five received a weak rating on the quality assessment tool, and none could be considered as being of high scientific quality after taking the risk of bias and other confounding variables into account. The studies demonstrated that lapatinib plus capecitabine is effective in extending median overall (OS) and progression-free survival (PFS) outcomes, achieving OS of 37.6 – 108.7 weeks and PFS of 21.1 – 30 weeks across studies. However, median OS and PFS for trastuzumab emtansine therapy were found to be considerably better (133.9 weeks and 41.6 weeks, respectively) than for lapatinib plus capecitabine. Conclusion: The results suggest that the combination of lapatinib plus capecitabine can improve PFS and OS in patients with HER2-positive breast cancer that has progressed on trastuzumab. However, it appears that trastuzumab emtansine provides better treatment outcomes in this context.",
keywords = "breast cancer, Capecitabine, Combination therapy, HER2-positive, Lapatinib, Systematic review, T-DM1, Trastuzumab, Trastuzumab emtansine",
author = "Rebecca Madden and Sam KOSARI and Gregory Peterson and Nasser Bagheri and Jackson THOMAS",
year = "2018",
month = "1",
day = "1",
doi = "10.5414/CP203123",
language = "English",
volume = "56",
pages = "72--80",
journal = "International Journal of Clinical Pharmacology Therapy and Toxicology",
issn = "0946-1965",
publisher = "Dustri-Verlag Dr. Karl Feistle",
number = "2",

}

Lapatinib plus capecitabine in patients with HER2-positive metastatic breast cancer : A systematic review. / Madden, Rebecca; KOSARI, Sam; Peterson, Gregory; Bagheri, Nasser; THOMAS, Jackson.

In: International Journal of Clinical Pharmacology and Therapeutics, Vol. 56, No. 2, 01.01.2018, p. 72-80.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Lapatinib plus capecitabine in patients with HER2-positive metastatic breast cancer

T2 - A systematic review

AU - Madden, Rebecca

AU - KOSARI, Sam

AU - Peterson, Gregory

AU - Bagheri, Nasser

AU - THOMAS, Jackson

PY - 2018/1/1

Y1 - 2018/1/1

N2 - Objective: Human epidermal growth factor receptor 2 (HER2)-positive breast cancer, which accounts for 20 – 25% of cases of breast cancers, is highly aggressive. Due to cardiotoxicity and increasing resistance associated with trastuzumab, the first-line treatment, there is a need for effective second-line therapies in treating HER2-positive breast cancer. In this context, there has been increasing interest in the combination of lapatinib plus capecitabine. The aim of this systematic review was to assess the efficacy of lapatinib plus capecitabine for HER2-positive breast cancer after progression with trastuzumab therapy, in comparison with capecitabine monotherapy and other agents such as vinorelbine and trastuzumab emtansine. Materials and methods: We performed a keyword search in five electronic databases (OVID MEDLINE, the Cochrane Library, Web of Science, SCOPUS, and CINAHL; January 2010 to April 2017) for trials in patients with HER2-positive breast cancer that has progressed on trastuzumab. After screening, the relevant studies were assessed for their methodological quality (including selection bias, randomization, control for confounders, and blinding) by two reviewers independently. Results and discussion: A total of 50 studies were identified; only 6 of those met the inclusion criteria and were analyzed. Five received a weak rating on the quality assessment tool, and none could be considered as being of high scientific quality after taking the risk of bias and other confounding variables into account. The studies demonstrated that lapatinib plus capecitabine is effective in extending median overall (OS) and progression-free survival (PFS) outcomes, achieving OS of 37.6 – 108.7 weeks and PFS of 21.1 – 30 weeks across studies. However, median OS and PFS for trastuzumab emtansine therapy were found to be considerably better (133.9 weeks and 41.6 weeks, respectively) than for lapatinib plus capecitabine. Conclusion: The results suggest that the combination of lapatinib plus capecitabine can improve PFS and OS in patients with HER2-positive breast cancer that has progressed on trastuzumab. However, it appears that trastuzumab emtansine provides better treatment outcomes in this context.

AB - Objective: Human epidermal growth factor receptor 2 (HER2)-positive breast cancer, which accounts for 20 – 25% of cases of breast cancers, is highly aggressive. Due to cardiotoxicity and increasing resistance associated with trastuzumab, the first-line treatment, there is a need for effective second-line therapies in treating HER2-positive breast cancer. In this context, there has been increasing interest in the combination of lapatinib plus capecitabine. The aim of this systematic review was to assess the efficacy of lapatinib plus capecitabine for HER2-positive breast cancer after progression with trastuzumab therapy, in comparison with capecitabine monotherapy and other agents such as vinorelbine and trastuzumab emtansine. Materials and methods: We performed a keyword search in five electronic databases (OVID MEDLINE, the Cochrane Library, Web of Science, SCOPUS, and CINAHL; January 2010 to April 2017) for trials in patients with HER2-positive breast cancer that has progressed on trastuzumab. After screening, the relevant studies were assessed for their methodological quality (including selection bias, randomization, control for confounders, and blinding) by two reviewers independently. Results and discussion: A total of 50 studies were identified; only 6 of those met the inclusion criteria and were analyzed. Five received a weak rating on the quality assessment tool, and none could be considered as being of high scientific quality after taking the risk of bias and other confounding variables into account. The studies demonstrated that lapatinib plus capecitabine is effective in extending median overall (OS) and progression-free survival (PFS) outcomes, achieving OS of 37.6 – 108.7 weeks and PFS of 21.1 – 30 weeks across studies. However, median OS and PFS for trastuzumab emtansine therapy were found to be considerably better (133.9 weeks and 41.6 weeks, respectively) than for lapatinib plus capecitabine. Conclusion: The results suggest that the combination of lapatinib plus capecitabine can improve PFS and OS in patients with HER2-positive breast cancer that has progressed on trastuzumab. However, it appears that trastuzumab emtansine provides better treatment outcomes in this context.

KW - breast cancer

KW - Capecitabine

KW - Combination therapy

KW - HER2-positive

KW - Lapatinib

KW - Systematic review

KW - T-DM1

KW - Trastuzumab

KW - Trastuzumab emtansine

UR - http://www.scopus.com/inward/record.url?scp=85041048973&partnerID=8YFLogxK

UR - http://www.mendeley.com/research/lapatinib-plus-capecitabine-patients-her2positive-metastatic-breast-cancer-asystematic-review

U2 - 10.5414/CP203123

DO - 10.5414/CP203123

M3 - Article

VL - 56

SP - 72

EP - 80

JO - International Journal of Clinical Pharmacology Therapy and Toxicology

JF - International Journal of Clinical Pharmacology Therapy and Toxicology

SN - 0946-1965

IS - 2

ER -